יחס מחיר להכנסות חזויות: Amarin (AMRN)

How do global partnerships for the promotion of Vascepa impact the capitalization of Amarin Corporation plc (AMRN)? The expected P/S valuation provides the answer, with the current level sitting around 1.40. Business growth relies on attracting top marketers through a bonus system. However, the market image is recovering after the loss of some patents, although the therapeutic value of the drugs remains high.
AMRN (amarincorp.com): פילוחים אנליטיים ודוחות לפי אינדיקטורים

The lack of alternatives to the EPA drug for reducing cardiovascular risks ensures steady market demand for Amarin Corporation plc (AMRN), which is reflected in the scale of its operations. The current level of 1.40 on the company's expected P/S chart compares market value with projected revenue, allowing investors to filter out short-term volatility and assess the real value of the business relative to its future cash flows.